REDUCED SULFOXIDATION CAPACITY IN D-PENICILLAMINE INDUCED MYASTHENIA-GRAVIS

被引：2

作者：

SEIDEMAN, P

AYESH, R

机构：

[1] Department of Internal Medicine, Divisions of Rheumatology, Karolinska Institute, Danderyd

[2] Department of Pharmacology, St Mary's Hospital, Medical School, London

来源：

CLINICAL RHEUMATOLOGY | 1994年 / 13卷 / 03期

关键词：

PENICILLAMINE; ADVERSE REACTION; SULFOXIDATION CAPACITY; MYASTHENIA GRAVIS;

D O I：

10.1007/BF02242938

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Myasthenia gravis may be observed due to treatment with penicillamine (D-PA). The sulphoxidation capacity was measured in nine Swedish patients with rheumatoid arthritis (RA) who had developed myasthenia gravis toward D-PA. The results show that in eight of nine patients tested, this parameter was markedly reduced. A patient with poor sulphoxidation capacity has a twelve-fold greater risk of developing this rare side effect. The significance of this is discussed.

引用

页码：435 / 437

页数：3

共 12 条

[1]

Al-Waiz M., Ayesh R., Mitchell S.C., Idle J.R., Smith R.L., A genetic polymorphism of the N-oxidation of trimethylamine in humans, Clin Pharmacol Ther, 42, pp. 588-594, (1987)

[2]

Mahgoub A., Idle J.R., Dring L.G., Lancaster R., Smith R.L., Polymorphic oxidation of debrisoquine in man, Lancet, 2, pp. 584-586, (1977)

[3]

Mitchell S.C., Waring R.H., Haley C.S., Idle J.R., Smith L., Genetic aspects of the polymodally distributed sulphoxidation of S-carboxymethyl-L-cysteine in man, Br J Clin Pharmacol, 18, pp. 507-521, (1984)

[4]

Scadding G.K., Ayesh R., Brostoff J., Mitchell S.C., Waring R.H., Smith R.L., Poor sulphoxidation ability in patients with food sensitivity, Br Med J, 297, pp. 105-107, (1988)

[5]

Stein M., Patterson A., Offer R., Atkins C., Tenfel A., Robinson M., Adverse effects of D-penicillamine in rheumatoid arthritis, Ann Int Med, 92, pp. 24-29, (1980)

[6]

Waring R.H., Mitchell S.C., Shah R.R., Idle J.R., Smith R.C., Polymorphic sulphoxidation of S-carboxymethyl-L-cysteine in man, Biochem Pharmacol, 31, 19, pp. 3151-3154, (1982)

[7]

Emery P., Panayi G., Hustron G., Welsh K., Mitchell S., Shah R., Idle J., Smith R., Waring R., D-penicillamine induced toxicity in rheumatoid arthritis. The role of sulphoxidation status and HLA-DR3, J Rheumatol, 11, pp. 626-632, (1984)

[8]

Garlepp M.J., Dawkins R.L., Christiansen F.T., HLA-antigens and acetyl-choline receptor antibodies in penicillamine induced myasthenia gravis, B M J, 286, pp. 338-340, (1983)

[9]

Ayesh R., Scadding G., Mitchell S.C., Penicillamine-induced myasthenia gravis and sulphoxidation capacity in rheumatoid arthritic patients (Abstract), Br J Rheumatol, 25, (1986)

[10]

Ayesh R., Mitchell S.C., Waring R.H., Withrington R.H., Seifert M.H., Smith R.L., Sodium aurothiomalate toxicity and sulphoxidation capacity in rheumatoid arthritic patients, Br J Rheumatol, 26, pp. 197-201, (1987)

← 1 2 →